Introducing the EQA Pilot Studies 2025

At Aurevia, we actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We launch new pilot studies regularly and aim to increase our Labquality EQAS by Aurevia portfolio with 5-10 new EQA schemes every year.

We proudly launch this year's first pilot studies, which will be conducted starting in March. Registration for these pilots is open until 24 February 2025. More details and registration links are provided below. The pilots are free of charge for a limited number of participants.

Read more about the pilots here and register by 24 February 2025!

Bacterial Vaginosis and Vaginitis Multiplex, Nucleic Acid Detection (5305)

The scheme is intended for clinical laboratories diagnosing bacterial vaginosis based on the detection of specific bacterial nucleic acids (Gardnerella vaginalis, Atopobium vaginae, BVAB2, Megasphaera 2, and Lactobacillus spp.). Detection of Candida and Trichomonas vaginalis are also included in the scheme. The pilot round includes three swab samples that should be analysed as regular patient samples.

Gram Stain, Vaginal Fluid (5043)

The samples in this scheme are digital images of Gram-stained vaginal fluid samples including brief case histories. No physical samples will be sent to the client.

HPV-Associated Head and Neck Cancer (6800)

The scheme is intended for both clinical pathology and virology laboratories. According to the need of the participant, the test round includes either one or two sample types. Paraffin sections are intended for p16 immunohistochemical staining (IHC) and paraffin scrolls for HPV nucleic acid detection. Samples should be analysed as regular patient samples according to the laboratory process.

Human Erythropoietin and Thrombopoietin (2708)

Please note that you can participate in this pilot study for both analytes or only either one analyte individually. The scheme is suitable for different assays and includes two lyophilized serum samples. Results will be evaluated according to method groups based on chemical principles and result levels

Immunosuppressants (2756)

We are introducing a new EQA scheme for immunosuppressive drugs including ciclosporin, tacrolimus, sirolimus and everolimus, The scheme is suitable for different assays and includes lyophilized EDTA blood samples. Results will be evaluated according to method groups based on chemical principles and result levels.

Find more information about the pilot studies here.